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Poliomyelitis has appeared in epidemic form, become endemic on a global scale, and been reduced to near-
elimination, all within the span of documented medical history. Epidemics of the disease appeared in the late 19th
century in manyEuropean countriesand North America, following which polio became a global disease with annual
epidemics. During the period of its epidemicity, 1900–1950, the age distribution of poliomyelitis cases increased
gradually. Beginning in 1955, the creation of poliovirus vaccines led to a stepwise reduction in poliomyelitis,
culminating in the unpredicted elimination of wild polioviruses in the United States by 1972. Global expansion of
polio immunization resulted in a reduction of paralytic disease from an estimated annual prevaccine level of at least
600,000 cases to fewer than 1,000 cases in 2000. Indigenous wild type 2 poliovirus was eradicated in 1999, but
unbroken localized circulation of poliovirus types 1 and 3 continues in 4 countries in Asia and Africa. Current
challenges to the ﬁnal eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses
in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses,
and persistent excretion of vaccine-derived poliovirus by a few vaccinees with B-cell immunodeﬁciencies. Beyond
the current efforts to eradicate the last remaining wild polioviruses, global eradication efforts must safely navigate
through an unprecedented series of endgame challenges to assure the permanent cessation of all human polio-
virus infections.
epidemiology; history of medicine; poliomyelitis; poliovirus; vaccines
Abbreviations: cVDPV, circulating vaccine-derived poliovirus; IPV, inactivated poliovirus vaccine; mOPV, monovalent oral polio-
virus vaccine; OPV, oral poliovirus vaccine; VAPP, vaccine-associated paralytic poliomyelitis; VDPV, vaccine-derived poliovirus.
From the viewpoint of medical history, the epidemiology
of poliomyelitis provides an intriguing and instructive case
study. Each new stage in the history of poliomyelitis was
unpredicted at the time of its occurrence. First, polio is one
of the few major diseases whose appearance in epidemic
guise was so recent that it was very well documented, to-
gether with its emergence as a worldwide scourge. Second,
the application of 2 different vaccines—inactivated poliovi-
rus vaccine (IPV) or Salk vaccine (1) and oral poliovirus
vaccine (OPV) or Sabin vaccine (2)—has resulted in a dra-
matic reduction in paralytic poliomyelitis, constituting one
of the most successful public health programs ever con-
ducted on a global scale (3). Third, the ‘‘endgame’’ in polio
eradication has offered some unexpected challenges that are
so difﬁcult it is hard to foresee the eventual outcome. In this
review, we highlight these phenomena, offer some specula-
tive epidemiologic interpretations, and update an earlier re-
view of poliomyelitis epidemiology published about 30
years ago (4), before the launch of international polio erad-
ication initiatives (5, 6).
BACKGROUND: HUMAN INFECTION WITH
POLIOVIRUSES
Biology of poliovirus
Polioviruses are enteroviruses that are transmitted from
person to person following excretion in feces and pharyn-
geal secretions, mainly via the hand-to-hand-to-mouth
route. Because the poliovirus receptor is only expressed
1213 Am J Epidemiol 2010;172:1213–1229on cells of humans and a few subhuman primate species,
there are no known extrahuman reservoirs (7, 8). Following
infection, thevirus replicates in the gastrointestinal tract and
may cause viremia (9, 10). Occasionally, the virus then in-
vades the central nervous system and destroys lower motor
neurons, causing a clinically distinctive ﬂaccid paralysis
without permanent sensory loss (11). The average incuba-
tion period for paralysis is approximately 10 days (range,
5–25 days) (12, 13). Only 1 in 150 primary poliovirus
infections causes paralytic poliomyelitis; since most infec-
tions are subclinical, paralytic cases represent only the ‘‘tip
of the epidemiologic iceberg’’ (4). Polioviruses canbe sorted
into 3 different antigenic types (types 1, 2, and 3) that are
based on their ability to induce protection against second
paralytic attacks (14) and are conﬁrmed by neutralization
tests (15). In the prevaccine era in the United States (16),
it was observed that the 3 poliovirus types varied substan-
tiallyintheirparalytogenicity(Table 1);type 1accountedfor
approximately 80% of paralytic cases (17, 18).
IPV is formulated as a trivalent product containing a rep-
resentative virus isolate of each antigenic type. OPV is usu-
ally formulated as a trivalent product, but monovalent OPV
(mOPV) formulations for each serotype (mOPV1, mOPV2,
and mOPV3) were used in the United States from 1961 to
1964, and both monovalent (primarily mOPV1) and bivalent
formulations have been used in other countries since the
1960s (19). Trivalent OPV is used in many countries for
routine immunization and supplemental immunization ac-
tivities (mass campaigns); mOPV1 and mOPV3 were li-
censed in 2005 and bivalent OPV (types 1 and 3) was
licensed in 2009 for use in supplemental immunization ac-
tivities in polio-endemic countries (20, 21). The properties
of both vaccines have been described in detail (22, 23).
Elimination and eradication of poliovirus
Various deﬁnitions have been used to describe the stages
of prevention of infectious diseases, ranging from local con-
trol of the disease to elimination of disease or infection
within a deﬁned geographic area to global eradication of
the infectious agent (24). It has been possible to certify
the disappearance of indigenous wild polioviruses in entire
countries and large geographic regions (25–27) because the
nucleotide sequences of wild polioviruses indigenous to dif-
ferent parts of the world are readily distinguishable (28). In
this review, we have adopted these general deﬁnitions (24);
we use ‘‘elimination’’ to mean the absence of circulating
indigenous wild polioviruses and ‘‘eradication’’ to mean the
absence of circulating vaccine-derived poliovirus (VDPV)
as well as wild polioviruses.
POLIOMYELITIS EMERGES: ANCIENT HISTORY AND
THE EARLY OUTBREAKS, THROUGH 1916
Early history
Although the historical record is very fragmentary and
must be interpreted with caution, there is a general consen-
sus that isolated cases of poliomyelitis have been occurring
for many millennia (18). The most compelling ancient case
is pictured on an Egyptian stele dating from the 18th dy-
nasty (1580–1350 BCE) showing an adult with a withered,
ﬂaccid leg and crutch; the image is strikingly similar to
a modern image of a young man with paralytic poliomyelitis
(29). Another convincing example is the description by
Walter Scott of his attack of acute ‘‘infantile paralysis’’ at
age 18 months in 1773, which left him with a permanent
limp (18). The disease’s striking presentation, in which
previously healthy infants underwent an acute febrile illness
followed by localized paralysis, would have made outbreaks
conspicuous. However, few if any cases were reported until
late in the 19th century.
Beginning around 1880, a series of outbreaks of infan-
tile paralysis were reported from several Scandinavian
countries and the United States. The abrupt appearance
of epidemic poliomyelitis is illustrated in Figure 1, which
shows data from the countries where the ﬁrst outbreaks
were recorded (30). Most remarkable is the almost simul-
taneous appearance of outbreaks in European countries
and the United States. Also notable is the absence of out-
breaks in the rest of the world, as illustrated by Cuba and
Brazil.
Polio deconstructed: the appearance of epidemics
What accounts for this striking phenomenon? The most
probable hypothesis is that outbreaks were associated with
an increase in the age at which poliovirus infection was
occurring (4). In the pre-epidemic era, enteric infections
were so ubiquitous that most infants were infected within
6–12 months, at a time when they had circulating antibodies
passively derived from their nursing mothers. Although se-
rum antibodies did not prevent enteric infection, they were
sufﬁcient to preclude viremia, thereby avoiding invasion of
the central nervous system and paralysis. The result was the
acquisition of active immunity under the cover of passive
protection. However, with the advent of improved personal
hygiene and public sanitation, the transmission of enteric
infections was delayed so that some infants were ﬁrst in-
fected after 12 months of age, when levels of passive
Table 1. Ratio of Paralytic Poliomyelitis Cases to Number of
Infections for the 3 Serotypes of Poliovirus, Assuming an Overall
Ratio of 1:150
a
Poliovirus
Serotype
%o f
Paralytic
Cases
No. of Paralytic
Cases per 100
Infections
No. of Infections
per Paralytic
Case
1 79 0.526 190
2 8 0.053 1,886
3 13 0.087 1,149
Total 100 0.667 150
a The distribution of paralytic cases by serotype was based on
unpublished laboratory studies on typing of poliovirus isolates for
the United States for 1955, as reported by the Centers for Disease
Control and Prevention (17). The ratio of 0.667 paralytic cases per
100 infections is the median of values from the 15 studies cited in
Table 9 (4). The breakdown by serotype was computed from these
data.
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sion of the central nervous system. Consistent with this
hypothesis, all of the early outbreaks occurred among very
young children, and the disease was known as ‘‘infantile
paralysis.’’
What is the evidence for this hypothetical explanation?
Although the evidence is circumstantial, there are a number
of observations that support the hypothesis. First, the earli-
est outbreaks occurred in countries where hygiene and
sanitation were most advanced. As public health improved
in less developed countries, outbreaks followed, over
a period of 60 years from about 1890 to 1950 (18, 31).
Second, once polio became established, the age distribution
gradually increased over many years, consistent with an
increasing delay in initial infections (discussed further
below). Third, in pre-epidemic countries, a high proportion
of infants transitioned from passive antibodies to active
antibodies without a seronegative gap (32).
Figure 1. Reported numbers of paralytic cases in poliomyelitis epidemics occurring between 1880 and 1916, by country and year, including the
countries where large outbreaks were ﬁrst observed. Data were obtained from chart 1 in the article by Lavinder et al. (30).
Epidemiology of Poliomyelitis 1215
Am J Epidemiol 2010;172:1213–1229Additional evidence for the hypothesis is provided by the
classic study by Paul and Horstmann (32) in Casablanca,
Morocco (Table 2). In the 1950s, Casablanca had 2 sizeable
populations, native Moroccans and Europeans. During the
period 1947–1953, there were cases of paralytic poliomy-
elitis in both populations, but the attack rate was 20-fold
higher in the European sector. Furthermore, the Moroccan
cases occurred mainly in infants, while many of the Euro-
pean cases appeared in older children and young adults. It
appears that Casablanca was a microcosm of the dynamics
that led to the appearance of poliomyelitis as an epidemic
disease. In 2010, the age distribution of paralytic poliomy-
elitis in Nigeria (33) and India (34) is similar to that seen in
the native population of Casablanca in the 1950s.
POLIOMYELITIS ASCENDANT: ANNUAL EPIDEMICS IN
THE UNITED STATES, 1916–1954
In the United States, beginning in the early 1900s, annual
epidemics of poliomyelitis occurred with regularity until the
introduction of IPV in 1955. During these years, the age
distribution gradually increased, as illustrated in Figure 2
(35). Again, this suggests that gradual improvements in san-
itation and hygiene reduced the circulation of enteric infec-
tions. However, in the instance of poliomyelitis, these
advances did not abate the disease but merely deferred it
to older age groups.
More disputable is the question of whether the increasing
age of poliovirus infection was accompanied by an increase
in disease burden. Figure 3 shows 2 contrasting data sets
(36–40). The upper panel sets forth data for the United
States in which average incidence appears to be quite con-
stant from 1915 to 1944, with an increase during the period
Table 2. Incidence of Paralytic Poliomyelitis in European and
Native Moroccan Populations, Casablanca, Morocco, 1947–1953
a
Cultural Background
European Moroccan
Total population 125,000 530,000
No. of paralytic poliomyelitis
cases
117 25
Average annual attack rate per
100,000 population
13.4 0.7
Age group of patients
from 1953, years
<28 9
2–9 15 2
10–39 5 0
a Data were obtained from Paul and Horstmann (32).
Figure 2. Age distribution of patients with poliomyelitis (paralytic
and nonparalytic) in Massachusetts, 1912–1952. Data were obtained
from Dauer (35).
Figure 3. Annual poliomyelitis attack rates per 100,000 population
in the United States (top) and New York City (bottom) during the ﬁrst
half of the 20th century. Upper panel: poliomyelitis incidence by
5-year period, United States, 1915–1954. Reports for 1915–1944
were almost entirely on cases of paralytic poliomyelitis, while reports
for 1945–1954 comprised approximately equal numbers of paralytic
and nonparalytic cases. Data were obtained from Serﬂing and
Sherman (36) Sabin (37), and the Centers for Disease Control and
Prevention (40). Lower panel: poliomyelitis incidence by 10-year
period, New York City, 1910–1954. Data were obtained from
Sabin (37), Greenberg et al. (38), and Siegel et al. (39).
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the numbers are approximately doubled by the inclusion
of nonparalytic cases, which were not reported prior to
1945. Furthermore, another large data set for New York
City, shown in the lower panel of Figure 3, failed to show
any increase in average annual incidence during the period
1910–1954.
Polio deconstructed: does the case:infection ratio
increase with age?
Another perspective on this question is provided by pro-
spective studies of the age-speciﬁc case:infection ratio.
Table 3 shows data from a 1952 study in which the popu-
lation was sampled for antibodies before and after an
outbreak, to estimate the number of seroconverters in
different age groups (41). The number of paralytic cases
per 100 seroconverters was then computed for each age
group. Although the case:infection ratio may have been
somewhat lower for infants, there was no evidence of an
increased ratio from age 3 years to age 14 years. This study
is consistent with the New York City data, which failed to
show an increase in incidence during a period when the age
distribution gradually rose (38, 39).
In addition to the case:infection ratio, there are other
ways to ask whether there is an age-speciﬁc increase in
the severity of paralytic poliomyelitis. The case-fatality rate
is the proportion of paralytic patients who die during the
acute phase of the disease (within 1–2 months of onset, in
contrast to the postpolio syndrome, which has onset many
years after the acute illness). Another perspective is the
distribution of sites of paralysis among paralytic cases,
which reﬂects the severity of the acute illness, the risk of
death, and the degree of long-term disability. One of the best
studies of these parameters is the report by Olin (42), who
analyzed data for Sweden for the years 1905–1950, a period
during which there was a stepwise increase in the age dis-
tribution. Table 4 shows the case-fatality rates in Sweden
during this period, which were remarkably stable over a 40-
year interval. However, when the same data set is analyzed
on an age-speciﬁc basis (Table 5), a quite different picture
emerges. The case-fatality rate increases very substantially
with age, and this reﬂects the age-speciﬁc differences in the
distribution of paralysis. At the youngest age (<3 years),
only 19% of cases have involvement of either both arms and
legs or the respiratory system (the most severe paralytic
categories), while among patients aged 25 years or older,
55% of cases fall into this category. Increased case-fatality
rates in older age groups were observed in many countries in
the prevaccine era (43) and are also being observed in the
recent polio outbreak in Tajikistan (44).
In summary, while the data fail to provide convincing
evidence of an age-speciﬁc increase in the ratio of paralytic
cases to infections, there is substantial evidence that among
Table 3. Age-Speciﬁc Case:Infection Ratios Observed During a Poliomyelitis Outbreak Among
Children Under Age 15 Years, North Carolina, 1948
a
Age
Group,
years
Total
Population
Proportion of
Seroconverters
No. of
Seroconverters
No. of
Paralytic
Cases
No. of Cases
Per 100
Seroconverters
<1 1,800 5/20 450 3 0.66
1–2 3,900 10/39 1,000 10 1.00
3–4 3,600 7/34 741 12 1.62
5–9 7,300 8/56 1,042 25 2.40
10–14 6,300 5/44 716 13 1.82
a The proportion of seroconverters is the ratio of the number of seroconverters to the total
number of subjects tested and was multiplied by the age-speciﬁc population for estimation of
the number of seroconverters in the population. Data were obtained from Melnick and Ledinko
(41).
Table 4. Chronologic Trends in the Poliomyelitis Case-Fatality
Rate in Sweden, 1905–1944
a
1905 1911–1913 1925–1934 1935–1944
No. of paralytic
cases
868 6,775 4,156 11,455
No. of deaths 145 1,239 624 1,594
Case-fatality
rate, %
16.7 18.3 15.0 13.9
a Data were obtained from Olin (42).
Table 5. Age-Speciﬁc Poliomyelitis Case-Fatality Rates and Age-
Speciﬁc Sites of Paralysis in Sweden, by Age Group, 1925–1944
a
Age Group, years
<3 3–6 7–14 15–24 ‡25
Case-fatality rate
(n ¼ 15,611), %
4.5 6 11 18 23.5
Location of paralysis
(n ¼ 15,303), %
Leg(s) only 58 40 34 23 20
Arm(s) only 10 9.5 10 10.5 10
Arm(s) plus leg(s) 17 27 33 38 37
Respiratory system 2 4 7 15 18
Other sites 13 19.5 16 13.5 15
Total 100 100 100 100 100
a Data were obtained from Olin (42).
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markedly from infancy to adulthood.
Virulence of poliovirus serotypes
During the period when poliomyelitis was pandemic in
the United States, there were marked year-to-year differ-
ences in the incidence of disease in any 1 city or region
and also marked region-to-region differences in any 1 year.
This phenomenon is illustrated in Table 6, showing a study
conducted in the United States during 1952, a high-
incidence year for the whole country (16). The data were
broken down by reporting region, and the regions were
grouped according to attack rate. The rates in high-
incidence regions exceeded those in low-incidence regions
by at least 10-fold. Table 6 also shows the distributions of
the 3 serotypes of poliovirus isolates for regions with dif-
ferent incidences. Strikingly,inthehighest-incidence regions,
94% of isolates were type 1, while only 6% were types 2 and
3 combined. In the lowest-incidence regions, 59% of iso-
lates were type 1 and 41% were types 2 and 3 combined.
Similar observations were subsequently made in polio-
endemic developing countries (45–48). These data suggest
considerable differences in the average virulence (paralyto-
genicity) of the 3 poliovirus types. In turn, this implies that
virulence differences were probably signiﬁcant contributors
to the incidence variations described above.
Seasonality
Prior to the vaccine era, poliomyelitis was a very seasonal
disease in temperate zones, as shown in Figure 4 (36, 49).
Furthermore, there was a hierarchy in the degree of season-
ality, which was most marked in colder climates and grad-
ually decreased toward the equator, so that it was almost
absent in the tropics (Figure 5) (36, 50, 51).
Polio deconstructed: the mechanism of seasonality
Although there is no deﬁnitive explanation for polio sea-
sonality, there are some data worth pondering (4). One hy-
pothesis is that seasonality reﬂects seasonal variations in
human activity, which in turn inﬂuences the probability of
person-to-person transmission of enteric infections. A com-
parison of poliomyelitis with other human enteric infections
provides a test of this idea. Figure 4 compares the seasonal
variation in rotavirus isolations with the seasonality of
poliomyelitis cases. Both viruses show marked seasonal vari-
ation but—strikingly—the 2 curves are almost mirror images,
with peaks about 6 months apart. This suggests that season-
ality is not a reﬂection of variations in human activity but
perhaps reﬂects the biologic properties of different viruses.
Another set of relevant data is provided by a comparison
of temperate and tropical regions, as shown in Figure 5. For
poliomyelitis in New England, the peak-to-trough ratio was
approximately 100-fold, while it was only 4-fold in Hawaii.
Furthermore, when seasonal variation in relative humidity is
plotted for the same regions, the relative humidity shows
marked seasonality in New England but is almost constant
throughout the year in Hawaii. Could extrahuman survival
of poliovirus vary according to relative humidity and
thereby inﬂuence the probability of transmission? Actually,
there are some old data that suggest that poliovirus survives
poorly below 40% relative humidity—exactly when polio-
myelitis transmission is infrequent in New England (52). It
is interesting that a similar hypothesis has been suggested
for the seasonality of inﬂuenza, except that the parameters
are reversed, in that inﬂuenza—which peaks in the
winter—survives better under cold and dry conditions
(53). However, until further studies are done, this hypothesis
will remain speculative.
Seasonality has been an important enabling factor for the
eradication of wild polioviruses in developing countries.
Mass immunization campaigns in the cooler months, when
the transmission chains of poliovirus (and potentially com-
peting enteroviruses) are at their seasonal low (54), have
been a mainstay of eradication efforts (45, 55, 56). In the
northern Andean region, polio circulation ceased in cities
in the temperate highlands years before it ceased in cities
of the tropical coastlands (57). In temperate Bolivia, OPV
Table 6. Distribution of Poliovirus Isolates by Serotype in Areas
With Different Attack Rates, United States, 1952
a
Attack Rate Per
100,000 Population
for Each Quartile
No. of
Isolates
% of Isolates for Each
Regional Group
Type 1 Type 2 Type 3
103–445 270 94 4 2
43–94 156 77 10 13
16–40 235 77 20 3
4–15 133 59 28 13
a The country was divided into 32 geographic regions that were
grouped into quartiles according to their attack rates; the virus iso-
lation data were then collated for each quartile. Data were obtained
from Shelokov et al. (16).
Figure 4. Seasonal variation in reported poliovirus (striped bars) in
New England during 1942–1951 and in isolation of rotavirus (dashed
line) in the United States during 1991–1997. Data were obtained from
Serﬂing and Sherman (36) and To ¨ro ¨k et al. (49).
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(58). Genetic data showed that wild poliovirus was imported
from coastal Peru into the Bolivian highlands (28).In Brazil,
polio was rapidly controlled in the south, but reservoirs
persisted in the northeast, which has a more tropical climate
as well as poor sanitation. Polio had already been eradicated
from the temperate southern cone of South America (Argen-
tina, Chile, Paraguay, and Uruguay) before the launch of the
Polio Eradication Initiative in the Americas (5). In China,
polio persisted in the provinces of the southeast but not in
the coastal northeast (59–61). One caveat is that the level of
immunization is usually higher in temperate zones than in
tropical zones.
POLIOMYELITIS IN RETREAT: FROM IPV TO
ERADICATION OF INDIGENOUS WILD POLIOVIRUSES
IN THE UNITED STATES, 1955–1973
Impact of polio vaccine
In the United States, IPV was introduced in 1955 and
OPV in 1961. Both vaccines were designed to protect im-
munized recipients. However, it was recognized that OPV
might also spread from vaccinees to their unvaccinated close
contacts, thereby increasing the level of immunity in the
population (62). In the United States, experience with other
vaccines had shown that it was difﬁcult to immunize more
than 80%–90% of the children in the population, particu-
larly if 2 or 3 doses were required for maximum immune
responses. Consistent with that view, serosurveys conducted
in the 1960s indicated that 5%–10% of children lacked an-
tibodies to each poliovirus type (63, 64). With a calculated
susceptible population of approximately 10 million for each
poliovirus type, it was assumed that wild polioviruses would
circulate indeﬁnitely. Reduction in paralytic poliomyelitis
was the goal of public health programs, and no one consid-
ered the possibility of eradication.
Following the introduction of IPVand OPV in the United
States, annual incidence fell exponentially, beginning in
1955 (Figure 6, upper panel) (65). The date of the last
indigenous wild poliovirus case in the United States is un-
certain. Wild poliovirus type 1 isolates associated with out-
breaks in southern Texas (1970) and Connecticut (1972)
were closely related to viruses indigenous to Mexico (66),
but sustained poliovirus circulation on both sides of the
United States-Mexico border could not be ruled out. With-
out much fanfare, the last cases of poliomyelitis due to
possibly indigenous wild polioviruses occurred in 1972.
From this date onward, all residual cases were either
vaccine-associated paralytic poliomyelitis (VAPP) or cases
imported from Mexico or acquired by persons traveling
abroad. The last US polio outbreak occurred in 1979 in an
underimmunized Amish population (67, 68), caused by
a wild poliovirus imported from Turkey via the Netherlands
and Canada (66).
Polio deconstructed: the mechanism of wild poliovirus
eradication in the United States
Why did wild polioviruses disappear from the United
States in spite of a substantial population of susceptible
children and adults? One hypothesis focuses on the season-
ality of poliovirus transmission (67, 68). The generation
time (interval between 2 successive infections) for polio
infections is about 10 days. During the seasonal trough in
New England, in February and March, approximately 0.1%
of the total annual cases (and infections) occur in 1 gener-
ation period. If one makes a calculation for the prevaccine
era, for a hypothetical population of 1 million persons, it can
be estimated that—of the annual total of 20,000 poliovirus
infections—only about 20 occurred during a trough gener-
ation period. If the vaccine reduced the number of suscep-
tible persons by 90%–95%, then there would only be 1–2
infections during the trough. Under these circumstances,
Figure 5. Seasonal variation in poliomyelitis incidence(striped bars) and relative humidity (dashed line) in New England during 1942–1951and in
Hawaii during 1938–1952. Ratios show the degree of seasonal variation in poliomyelitis incidence. Data were obtained from Serﬂing and Sherman
(36), Enright (50), and the National Oceanic and Atmospheric Administration (51).
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tion could explain the temporary disappearance of wild
polioviruses from local areas.
For this hypothesis to explain the stepwise eradication of
wild polioviruses, it would be necessary to assume that,
following its disappearance, poliovirus was not readily re-
introduced from neighboring areas. The lower panel in
Figure 6 (69) provides some relevant data—namely, the
number of states reporting anycases of poliomyelitis in each
year during the period 1951–1980. Prior to the introduction
of poliovirus vaccines, each state reported some cases of
poliomyelitis every year. However, beginning with the in-
troduction of OPVaround 1961, the number of states report-
ing cases of polio due to wild polioviruses gradually
dropped, reaching zero in 1973. This suggests that not only
was poliovirus fading out ofindividual regions butit was not
being reintroduced or, if reintroduced, it was not able to
spread sufﬁciently to cause cases of paralytic poliomyelitis.
POLIOMYELITIS ON THE RUN: STEPS TOWARD
GLOBAL ERADICATION, 1973–2000
The disappearance of wild poliovirus in the United States
and other developed countries demonstrated the plausibility
of eradicating indigenous wild polioviruses in other regions.
Inspired by these examples and the successful control pro-
grams in Cuba (the ﬁrst country to successfully eradicate
wild poliovirus) and Brazil (55, 56, 70), the Pan American
Health Organization, under the leadership of Dr. Ciro de
Quadros, undertook a vigorous immunization campaign
with the goal of eradicating all wild polioviruses in the
Americas. As Figure 7 shows, this program was very effec-
tive, leading to eradication of all indigenous wild poliovi-
ruses by 1991 (25). In this instance, routine pediatric
immunization, supplemented with mass immunization cam-
paigns in the form of national and subnational immunization
days and mop-up campaigns in outbreak areas, provided at
least 3 doses of trivalent OPV to approximately 80% of
children by 12 months of age.
In 1988, the experience in the Americas emboldened the
World Health Assembly to set a goal for global eradication
of wild polioviruses (71). This campaign has been very
successful, as shown in Figure 8. Reported numbers of con-
ﬁrmed polio cases worldwide have been reduced from an
annual level of about 50,000 in 1980 to fewer than 1,000 in
2001. Because of gross underreporting of polio cases in
developing countries (72), the number of polio cases pre-
vented annually by vaccination is estimated at approxi-
mately 600,000 (6, 19, 23), so the current case count
represents a >99% reduction in the potential global polio
burden. Furthermore, paralytic cases due to type 2 wild
poliovirus were last reported in 1999 in Uttar Pradesh, India,
reinforcing the credibility of global eradication (73). By
Figure 6. Upper panel: annual numbers of reported cases of polio-
myelitis in the United States, 1951–1982. For the years 1973–1982,
cases were either imported cases or cases of vaccine-associated
paralytic poliomyelitis, with the exception of an outbreak that occurred
among the Amish population in 1979. Data were obtained from the
Centers for Disease Control and Prevention (65). Lower panel: num-
ber of US states reporting indigenous poliomyelitis due to wild polio-
viruses,1951–1982. Datawereobtainedfromthe Centersfor Disease
Control and Prevention (69).
Figure 7. Reported numbers of conﬁrmed cases of paralytic polio-
myelitis (solid line) in Latin America and the Caribbean region and
percentages of children aged 12 months given at least 3 doses of oral
poliovirus vaccine (OPV) (dashed line), 1969–1995. Data were ob-
tained from de Quadros et al. (5).
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endemic had shrunk from over 100 to fewer than 10; the
main residual foci are in Nigeria and a belt of Asian
countries extending from Afghanistan across Pakistan to
northern India (74).
POLIOMYELITIS FIGHTS BACK: POCKETS THAT DEFY
ERADICATION, 2000–2010
In the years leading up to 2000, there was an expectation
that global eradication of wild poliovirus was imminent.
However, that hope has been dashed by several unwanted
developments. As Figure 8 shows, since 2000, 500–2,000
cases have been reported each year, and incidence appears
to have reached a plateau. Wild polioviruses have continued
to be endemic in Nigeria and in northern India, as well as
Pakistan and Afghanistan. Furthermore, there has been pe-
riodic seeding of polioviruses from these endemic sources to
other countries in Africa, Southeast and Central Asia, and
Europe (Figure 9) (33, 44, 75, 76).
Polio deconstructed: persistence of wild polioviruses
Why has it been so difﬁcult to complete the eradication of
poliomyelitis, considering past successes in so many coun-
tries, including tropical nations, where all of the risk factors
prevail and resources are often limited? Explanations fall into
3 main categories: failure to vaccinate, failure of the vaccine,
andviralepidemiology.Eachmechanismappearstoplayarole
to varying degrees in different polio-endemic countries.
Failure to vaccinate
In Nigeria, underutilization of vaccine has been well
documented (77). A recent study (Figure 10) showed a cor-
relation between the attack rate for virologically conﬁrmed
cases of paralytic polio and the percentage of children under
age 5 years who had received at least 3 doses of OPV.
Nigeria reported 541 wild poliovirus cases in 2009, but only
6 wild poliovirus cases as of June 2010. Greatly improved
vaccine coverage in door-to-door immunization campaigns
in the northern states, where previously less than 40% of
young children had been well immunized, has apparently
brought the country to theverge of eradication ofindigenous
wild polioviruses (78). These recent observations indicate
that if all of the states in Nigeria reached the immunization
level achieved by those states with the most effective pro-
grams, it would be possible to stop all poliovirus circulation
in Nigeria.
Figure 8. Global incidence of poliomyelitis, reported as virologically
conﬁrmed cases of paralytic poliomyelitis, during the period 1980–
2009. Cases for 2000–2009 have been replotted in the inset to dem-
onstrate recent incidence. It is estimated that during the period from
1980 to the late 1990s, virologically conﬁrmed cases represented only
a modest proportion (15%–25%) of all cases of paralytic poliomyelitis.
Data were obtained from the World Health Organization (100).
Figure 9. Transmission of wild polioviruses worldwide in 2009. Countries with wild polioviruses are classiﬁed into 3 categories: those with
endemic polioviruses, those with imported viruses that have reestablished transmission, and those with recently imported viruses. Data were
obtained from the World Health Organization (33).
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ferent set of challenges. Afghanistan and Pakistan constitute
a single epidemiologic block, with ongoing cross-border
transmission accompanying the large population move-
ments between the 2 countries. Polio has been quickly con-
trolled by mass trivalent OPV campaigns in the accessible
areas of Afghanistan, but transmission has continued in 12
insecure districts in southern Afghanistan and along the
border with Pakistan. Northern Punjab is frequently re-
seeded by wild polioviruses from neighboring endemic
areas (79). The feasibility of eradication from both countries
has been demonstrated by the absence of locally indigenous
polioviruses in highly populous northern Punjab, where
OPV coverage rates have been highest.
Another related issue is the failure to immunize children
at a sufﬁciently early age. Where enteroviruses are circulat-
ing with high frequency, poliomyelitis manifests as ‘‘infan-
tile paralysis,’’ and infection often takes place in babies aged
6–12 months. Under these circumstances, it is critical to
immunizeveryyounginfantsbeforetheyareexposedtowild
polioviruses.Thiscanbedifﬁculttoachieveandmayrequire
continued house-to-house campaigns that are highly labor-
intensive. However, recent data from both Nigeria and India
on the age distribution of paralytic cases indicate that most
infections with wild polioviruses are occurring in infants
over 12 months of age (Table 7). This observation provides
a ‘‘window’’ for OPV immunization at ages 6–12 months.
Vaccine failure
During the development of OPV in the late 1950s, it was
observed that a number of variables inﬂuenced efﬁcacy, in-
cluding the ages of infants and the titer of passively acquired
maternal antibody, the season of year and the geographic
locale, and the titer of OPVand the number of doses admin-
istered (80). Another factor in developing countries is the
high prevalence of diarrheal disease, which can reduce the
efﬁcacyoforallyadministeredvaccines,includingOPV(81).
A phenomenon called ‘‘interference’’ was recognized in
these early studies. When OPV is administered to children
who are concurrently infected with other enteroviruses, the
proportion of vaccinees who become OPV-infected and de-
velop an immune response against poliovirus is reduced
(45). Furthermore, the 3 types of poliovirus in the vaccine
can interfere with each other. For this reason, when OPV
was ﬁrst introduced, it was formulated as monovalent OPV,
given in the sequence type 1, type 3, and type 2. In the late
1950s, many comparisons of monovalent OPVand trivalent
OPV were made; all studies showed that the ‘‘take rate’’ was
greater with monovalent OPV. However, conversion rates
were relatively high with trivalent OPV (50%–90%) in com-
parison with monovalent OPV (65%–95%). Even in tropical
areas with very high rates of intercurrent enteric virus in-
fections, conversion rates for trivalent OPV were rarely be-
low 50%. These observations were reﬂected in the evolving
vaccine policy in the United States. Monovalent OPV was
launched in the United States in 1961 and was used until
1964, when trivalent OPV was substituted, since the advan-
tages of a single vaccine were thought to outweigh the
slightly higher conversion rates with monovalent OPV (23).
Because of recent problems with persistence of wild po-
lioviruses, vaccine failure has been restudied in Nigeria and
India (77, 82). In contrast with historical data, trivalent OPV
has conferred much lower levels of protection (77, 82, 83).
Table 8 summarizes data from Nigeria, in which a single
dose of trivalent OPV was estimated to provide only
16%–18% protection against paralytic poliomyelitis. Sub-
sequent serologic studies have found substantially higher,
but still suboptimal, seroconversion rates in India (20, 21).
Viral epidemiology
Undoubtedly, the epidemiologic context has also contrib-
uted to the difﬁculty of eradication. As discussed above, in
tropical climates it is harder to interrupt transmission of
polioviruses because of the relative lack of seasonality and
the higher prevalence of enteric infections (81). Further-
more, transmission is enhanced in locales with high
Figure 10. Annual attack rate of type 1 paralytic poliomyelitis in
Nigeria according to the percentage of children under age 5 years
who were immunized with oral poliovirus vaccine ( 3 doses),
2001–2007. Data for 37 individual states for each of the 7 years were
sorted according to attack rate and the proportion of children immu-
nized. The data were then collated to construct each point on the
graph. Shown next to each point is the number of instances with the
parameters for that point. Data were obtained from Jenkins et al. (77).
Table 7. Age Distribution of Paralytic Poliomyelitis Cases Caused
by Wild Polioviruses in Nigeria, 2008 and 2009
a
Age Group,
months
% of Cases
2008 (n 5 782 Cases) 2009 (n 5 388 Cases)
0–11 6 6
12–23 34 28
24–35 33 34
36–47 18 15
48–59 5 9
 60 3 8
Total 99 100
a Data were obtained from the World Health Organization (33).
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both Uttar Pradesh and Bihar in India, as well as in Nigeria
and Pakistan. These epidemiologic parameters conspire
both to enhance the circulation of wild polioviruses in very
young infants and to reduce the effectiveness of OPV.
Strategies to reduce circulation of endemic wild
polioviruses
Several strategies are available for enhancing the control
of polio in endemic locales, including the use of monovalent
OPV, the use of bivalent OPV, the employment of enhanced
immunization programs, and the possible inclusion of IPV
(84). Recent experience with OPV (77, 83, 85) is quite
different from the early observations, in 2 respects: a much
lower conversion rate with trivalent OPVand a much greater
advantage of monovalent OPV. Particularly impressive is
the study by Jenkins et al. (77), which compared the effec-
tiveness of different vaccines for the prevention of virolog-
ically conﬁrmed paralytic poliomyelitis in Nigeria, a critical
test site for OPV (Table 8). Trivalent OPV showed effec-
tiveness rates of 16% and 18%, respectively, against type 1
and type 3 poliomyelitis, while mOPV1 showed 67% effec-
tiveness against type 1 disease.
Bivalent OPV containing both Sabin type 1 and Sabin
type 3 has been introduced into all 4 persistently endemic
countries, beginning in 2009 with Afghanistan (20, 21, 79).
Bivalent OPV has the advantage of eliminating interference
from the robust type 2 OPV component, while inducing
immunity comparable to that of mOPV1 and mOPV3.
Currently, the Global Polio Eradication Initiative uses 4 dif-
ferent OPV formulations: 1) trivalent OPVin routine immu-
nization, during national immunization days, and to respond
to circulating VDPV2 outbreaks; 2) bivalent OPV in mass
campaigns in areas endemic for wild polioviruses 1 and 3;
and 3) mOPV1 or 4) mOPV3 in some mass campaigns and
in mop-up campaigns implemented in response to cases and
to induce type-speciﬁc population immunity (20, 21).
POLIO FIGHTS BACK: THE DARK SIDE OF OPV,
2000–2010 (AND BEYOND)
During the early development of OPV, it was recognized
that candidatevaccine strains of poliovirus were excreted by
vaccinees and that some of these excreted viruses exhibited
increased paralytogenicity. Dr. George Dick summarized
the problem in his epigram, ‘‘in like a lamb, out like a lion’’
(86). Dr. Philip Minor sequenced isolates of OPV excreted
by vaccinees and, in collaboration with other investigators,
identiﬁed the point mutations that were associated with re-
version to enhanced virulence (11, 87). Following the in-
troduction of OPV immunization in the United States,
meticulous surveillance documented rare cases of VAPP
occurring in both vaccinees and their close contacts (88–
92) (Marjorie Pollack, Centers for Disease Control and
Prevention, personal communication, 1979). During the pe-
riod 1961–1999, there were 1–2 cases of VAPP per million
primaryimmunizationswithOPV. Forthe period1961–1999,
similar numbers of cases were reported in vaccinees and in
contacts. However, the relative distribution was inﬂuenced by
vaccine policy: When all family members were immunized,
almost all cases occurred in vaccinees (1961–1964); when
immunization was limited to children, the number of cases
in their parents and other contacts approached the number of
cases in vaccinees (1965–1999). Approximately 20% of cases
invaccine recipients occurred in children with hypo- or agam-
maglobulinemia, and some of these patients failed to clear
their infections and excreted immunodeﬁciency-associated
VDPVs for many years (93–96). The relative risk of VAPP
varies by serotype: Immunologically normal recipients are at
highest risk from type 3 virus, immunodeﬁcient recipients are
at highest risk from type 2, and contacts are at highest risk
from type 2. During the period 1997–1999, IPV was given
prior to OPV, and in 2000 an exclusive IPV policy was adop-
ted. Subsequently, no cases of VAPP have been reported in the
United States (92).
These observations established the plausibility of
community-wide spread of OPV leading to outbreaks of
poliomyelitis. However, since the introduction of OPV in
the United States in 1961, there have not been any reports
of such outbreaks. Outbreaks associated with circulating
VDPVs (cVDPVs) were ﬁrst recognized by sequence char-
acterization of isolates from polio cases in Hispaniola (Haiti
and the Dominican Republic) in 2000–2001 (97). Since
then, global surveillance has identiﬁed a number of such
outbreaks, summarized in Table 9 (96, 98–100).
Polio deconstructed: cVDPV outbreaks
Why were cVDPV-associated outbreaks ﬁrst identiﬁed
only in 2000, 40 years after the introduction of OPV? Sev-
eral factors contributed to the late recognition of this phe-
nomenon. First, the development of methods for rapid
sequencing of polioviruses made it possible to deﬁnitely
distinguish OPV-revertant viruses from wild polioviruses
(101).Second, thegradual establishment of an extraordinary
global network for the isolation and characterization of po-
lioviruses (102) during the period 1990–2000 facilitated re-
construction of the molecular epidemiology of such
outbreaks (97, 98). However, the most important reason
for the recent recognition of cVDPV-associated outbreaks
is that most cVDPV outbreaks have occurred when immu-
nization programs are very incomplete, with less than 50%
of children receiving 3 doses of OPV. In such situations,
Table 8. Estimated Protective Efﬁcacy of Trivalent and Monovalent
Oral Poliovirus Vaccines Against Type 1 and Type 3 Paralytic
Poliomyelitis, Nigeria, 2001–2007
a
Poliovirus
Type
No. of
Case-Control
Matches
Efﬁcacy of
Trivalent
OPV, %
95% CI
Efﬁcacy of
Monovalent
OPV, %
95% CI
1 1,174 16 10, 21 67 39, 82
3 1,092 18 9, 26 —
b
Abbreviations: CI, conﬁdence interval; OPV, oral poliovirus vac-
cine.
a Estimates were based on a case-control study design. Data were
obtained from Jenkins et al. (77).
b There was insufﬁcient use of monovalent type 3 OPV for reliable
estimation of efﬁcacy.
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spread infection, leading to outbreaks of paralytic disease.
This observation explains the relative infrequency of such
outbreaks and their absence in most regions where OPV
campaigns have reached a large proportion of the popula-
tion. For instance, in Cuba, OPV has been administered
during annual national immunization days that have satu-
rated the population (55, 103, 104). After such national
immunization days, surveillance of sewage has detected
OPV-related virus for about 3 months, following which it
disappears. Cuba, unlike nearby Haiti, has not experienced
cVDPV-associated outbreaks, and the probability of such
outbreaks is apparently low under these conditions.
Furthermore, the Global Polio Eradication Initiative has
fundamentally altered poliovirus ecology. In all but a few
districts in the world, immunity to poliovirus is no longer
conferred by natural infection but depends solely upon vac-
cination. In areas free of wild polioviruses, cVDPVs can
emerge if immunity gaps are allowed to develop. The mag-
nitude of the risk depends on the extent of immunization
gaps, the intensity of other environmental risks (sanitation,
hygiene, population density), and the poliovirus serotype
(type 2 > type 1 > type 3). It has become essential to
maintain high population immunity and sensitive surveil-
lance for acute ﬂaccid paralysis and poliovirus to avoid out-
breaks caused by cVDPVs or introduced wild polioviruses.
How extensive are VDPV outbreaks and how can they
best be controlled or prevented?
Table 9 summarizes the recognized conﬁrmed cVDPVout-
breaks, which appear not to require an immunodeﬁciency-
associated VDPV precursor infection (101). With the
exception of the type 2 outbreak in Nigeria, most outbreaks
have been relatively modest in extent, with fewer than 50
reported conﬁrmed paralytic cases. Of course, for each case
there are many more subclinical infections; depending
upon the case:infection ratio, there could be between 100
and >1,000 infections for each paralytic case. One recent
analysis estimated the number of cVDPV infections in the
millions (99). The number of outbreaks, particularly the
ongoing outbreak in Nigeria (96), indicates that cVDPVs
present a signiﬁcant obstacle to the eradication of virulent
polioviruses. In addition, the 1968 outbreak of almost 500
paralytic cases in Poland, which was caused by a candidate
attenuated type 3 vaccine strain (USOL-D-bac), underlines
the potential problem (105, 106).
Of the cVDPV outbreaks listed in Table 9, most were
ended by vigorous OPVimmunization responses that closed
the immunity gap among susceptible children, followed by
a fadeout of cVDPVs. However, a strategy of indeﬁnite use
of OPVis obviously fraught with danger, since it is unlikely
to lead to a world free of potentially dangerous polioviruses.
Eventually, it will be necessary to terminate the distribution
of OPV, requiring an ‘‘endgame’’ strategy for the global
eradication of circulating polioviruses.
THE ‘‘ENDGAME’’ IN POLIOVIRUS ERADICATION
Elimination of wild polioviruses
Once a country or continent has eliminated wild poliovi-
ruses through the use of OPV, public health authorities have
Table 9. Reported Numbers of Virologically Conﬁrmed Cases of Paralytic Poliomyelitis Associated With Vaccine-Derived Polioviruses, 1988–
June 2010
a
Country Poliovirus Type 1988–1998 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Egypt 2 30
Hispaniola (Haiti and the
Dominican Republic)
11 2 9
Philippines 1 3
Madagascar 2 4
China 1 3
Madagascar 2 5
Indonesia 1 46
Cambodia 3 1 1
Nigeria 2 1 21 68 63 153 9
Niger 2 2
Myanmar 1 1 4
Democratic Republic
of the Congo
2 14 2 3
Guinea 2 1
India 2 11 1
Ethiopia 3 15
Abbreviation: VDPV, vaccine-derived poliovirus.
a This table does not include 21 polio-compatible cases in Hispaniola and 10 polio-compatible cases in Indonesia that were not virologically
conﬁrmed. Both the Niger VDPVs and the Guinea VDPV were linked to the Nigerian VDPV2 outbreak. Data were obtained from Wringe et al. (99)
and the World Health Organization (100).
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of OPV immunization, transition from OPV to IPV, or care-
fully coordinated termination of OPV without IPV replace-
ment. In the United States, OPV immunization was
maintained for about 20 years following the elimination of
wild polioviruses in 1973. In the late 1990s, therewas a tran-
sition to IPV, via an intermediate stage of sequential IPV–
OPV, with IPV being the recommended vaccine since 2000
(92, 107). This transition was made primarily for 2 reasons:
1) in the absence of indigenous wild polioviruses in the
Americas,the continuingburdenof VAPP wasconsideredun-
acceptable, even though the frequency was only about 2 cases
per million primary immunizations; and 2) therisk ofacquisi-
tion of wild polioviruses, either through importation or during
international travel, mandated continued immunization.
Many other industrialized countries have followed a sim-
ilar strategy. An instructive example is the experience of
New Zealand, shown in Figure 11 (108). In February
2002, New Zealand switched from OPV to IPV. During
the transition, sewage was sampled periodically to deter-
mine the frequency of OPV-related viruses. Prior to the
switch, polioviruses were isolated from approximately
90% of sewage samples. Following the switch, the fre-
quency fell in a stepwise fashion, reaching 0% in about 4
months. Although there were occasional isolations of polio-
virus thereafter, it was concluded that these were OPV-
related viruses shed by visitors to New Zealand. This
conclusion was based on the small number of mutations
and the known evolution rate for polioviruses (57), implying
that these isolates were derived from OPV administered
elsewhere after the February 2002 cessation of OPV immu-
nization in New Zealand.
Polio deconstructed: the posteradication strategy
Let us assume for purposes of discussion that it is feasible
to eliminate wild polioviruses from those countries where
it is still endemic. There has been extensive discussion
among experts regarding alternative strategies for the post-
eradication endgame (109–116). Indeﬁnite continuation of
OPV carries several liabilities: continued cases of VAPP
(including new prolonged excretion of immunodeﬁciency-
associated VDPVs by immunodeﬁcient vaccinees); the
potential for new outbreaks caused by cVDPVs; and public
health ‘‘fatigue,’’ leading to reduced OPV coverage and its
attendant dangers. Termination of OPV without transition to
IPV carries the risk of initiating new outbreaks caused by
cVDPVs, because of either spread of cVDPV during the
termination phase or unregulated importation of OPV
from other countries. Additionally, this option carries the
ethical liability of a double standard for high- and low-
income countries. For these reasons, there is an evolving
(but not necessarily total) consensus that, in principle, the
optimal choice is a transition from OPV to IPV (109, 113–
115, 117).
The most important concerns about the IPV option have
focused on practical issues regarding the cost and global
coverage levels attainable with an injected vaccine as com-
pared with an oral vaccine (118). However, most middle-
and low-income countries are already using injected
vaccines for other diseases, so they could adopt IPVas either
an additional or incorporated product. IPV is more expen-
sive than OPV, and it has been estimated that it would cost at
least $1 billion to produce sufﬁcient IPV for developing
countries. In addition, there are issues pertaining to formu-
lation (a single product vs. incorporation of IPV with other
immunogens), dosage regimens, and recruitment of collab-
orating manufacturers with sufﬁcient production capacity
(119). Recently, the Global Polio Eradication Initiative un-
dertook to fund a research program for creation of an afford-
able IPV for developing countries (21, 118, 120), including
exploration of the efﬁcacy of fractional intradermal IPV
doses (121, 122). A key research question, which is the sub-
jectofseveralongoingandproposedstudies,isthe efﬁcacyof
IPV in preventing poliovirus circulation in the highest-
risk settings (21, 123).
CONCLUSIONS
There is an epidemiologic imperative to eradicate polio-
viruses, for several reasons: the recurring spread of wild
polioviruses from endemic sites to other countries; the po-
tential dangers of vaccination ‘‘fatigue’’ in countries that
have already eliminated wild polioviruses; and the docu-
mented dangers of cVDPV. It has also been argued that
eradication of polioviruses would cost less than control pro-
grams (124) and that there is an ethical imperative for erad-
ication (125).
Figure 11. Environmental surveillance for poliovirus excretion fol-
lowing the transition from oral poliovirus vaccine (OPV) to inactivated
poliovirus vaccine (IPV) in New Zealand, 2001–2003. Sewage sam-
ples were collected weekly from 3 different sewage treatment plants
before and after the termination of OPV utilization. Routine use of
OPV ended on February 1, 2002, and the prevalence of OPV in sew-
age fell from approximately 90% to 0% by June 2002 (4 months later).
During the following 10 months (July 2002–April 2003), there were 5
isolates of OPV; on the basis of sequence analysis, all of these iso-
lates were determined to be from children recently immunized with
OPV, suggesting that they represented imported OPV. Data were
obtained from Huang et al. (108).
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quirements must be met. First, in countries where wild po-
lioviruses still circulate, there must be a massive effort to
immunize a high proportion of very young infants with
OPV—perhaps followed by 1 or more doses of IPV. Second,
in countries where wild polioviruses are no longer circulat-
ing, there must be a transition from OPV to IPV to eliminate
VAPP and reduce the dangers of outbreaks associated with
cVDPVs. Finally, there must be continuation of rigorous
surveillance efforts to inform these programs, with a plan
for emergency intervention whenever polio outbreaks
occur. This strategy will require the coordinated effort of
international and national public health programs, supported
with sufﬁcient resources to produce and administer both
OPVand IPV. Only time will tell whether this strategy will
be implemented and, if implemented, whether it will
succeed.
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